GeminIQ

UnitedHealth (UNH) Q3 2026 Earnings: EPS Up 76%, $610M From Reserves

Chad Hartman

By

Published · Last updated

UnitedHealth Group (NYSE: UNH) reported Q3 FY2026 revenue of $112.69 billion, down 0.4% year over year, and diluted EPS of $4.56, up 76.1%, for the quarter ended September 30, 2026. The 8-K earnings release came October 13, 2026 and the 10-Q followed on November 3. Profit rose on shrinking sales because costs fell faster than premiums, and the 8-K discloses that $610 million of net favorable prior period reserve development sat inside that cost decline, roughly 0.7 points of premiums.

Field Value
Company UnitedHealth ($UNH)
Quarter Q3 FY2026, period ended September 30, 2026
Earnings release October 13, 2026 (Form 8-K)
10-Q filed November 3, 2026
Revenue $112.69 Billion (-0.4% YoY)
Diluted EPS $4.56 (+76.1% YoY)
Operating margin 5.8% (+2.0 pts YoY)
Operating cash flow (TTM) $25.09 Billion (nine months ended September 30, 2026, per the 10-Q)
Net favorable reserve development (per 8-K) $610 Million

UnitedHealth Q3 2026 Revenue, EPS and Operating Margin

UnitedHealth's Q3 2026 diluted EPS was $4.56, up 76.1% from $2.59, on revenue of $112.69 billion, down 0.4%.

A reader who sees EPS up 76% would expect revenue growth behind it. Instead premiums fell 2% and UnitedHealthcare served 1.8 million fewer people than a year earlier.

The Data: Earnings from operations rose 52.1% to $6.56 billion, an operating margin of 5.8% against 3.8%, yet 12 of the last 16 quarters earned more from operations. Net earnings attributable to shareholders rose 75% to $4.11 billion. GeminIQ's pre-calculated Operating Profit Margin on a trailing basis was 6.81%, up from 4.32%.

Why: Interest expense of $963 million and a $76 million loss on sale sit below operating income and barely moved, so a $2.25 billion operating gain became a $2.30 billion pretax gain on a smaller base: 52% growth became 71%. A tax rate of 22.2%, against 21.2%, took some back. Diluted shares of 902 million, the fewest of the last 16 quarters, added about one point, since EPS grew 76.1% against net income's 75.0%. With revenue flat, every dollar of the improvement sits in the cost lines.

UnitedHealth Q3 2026 income statement lines from the 10-Q, compared with the four prior quarters

GeminIQ Financial Statements shows `Earnings Per Share Diluted` of $4.56 in Q3 2026 against $2.59 a year earlier, with `Operating Income Loss` of $6,563 million against $4,315 million. The highlight marks the Q3 2026 EPS.

UnitedHealth operating income by quarter, last 16 quarters

GeminIQ Visualizations plots `Operating Income Loss` for the last 16 quarters. The highlight marks Q3 2026 at $6.6 billion, the fourth-lowest of the 16 despite its 52.1% year-over-year rise.

What UnitedHealth's Q3 2026 10-Q Shows Beyond the Press Release

UnitedHealth's Q3 2026 medical care ratio was 88.4%, down 1.5 points from 89.9%, and the 8-K credits medical cost management and pricing discipline while disclosing $610 million of net favorable prior period reserve development. That release accounts for about half of the improvement.

The Data: Medical costs fell $2.98 billion to $76.98 billion on premiums of $87.08 billion. Add the $610 million back and the ratio is 89.1%, only 0.8 points below last year, and operating income is $5.95 billion, up 38% rather than 52% (both derived). The 10-Q also records a $224 million net gain on portfolio divestitures inside operating costs. Together the reserve development and that gain are $834 million, 37% of the $2.25 billion operating increase (derived).

Why: The 10-Q lists favorable prior period reserve development among the drivers of the lower ratio, alongside fewer people served, affordability initiatives, pricing and benefit design. The filing gives no year-ago reserve figure, so the $610 million is not netted against Q3 2025; if last year's quarter also carried releases, the underlying improvement is larger. The sequential read is plainer. The 8-K for Q2 reported a ratio of 86.7%, so Q3's 88.4% is 1.7 points higher even with the release.

The 8-K led with an adjusted EPS of $4.69; the as-filed $4.56 already contains the release and the gain. A quarter whose margin gain depends on reserve estimates is only as durable as the estimates.

UnitedHealth Q3 2026 Cash Flow, Buybacks and Dividends

UnitedHealth's Q3 2026 operating cash flow was $5.12 billion, down 13.8% from $5.95 billion a year earlier and 53.6% below Q2's $11.05 billion. Cash conversion fell from 1.9 times net income in Q2 to 1.2 times, the 8-K's own measure.

The Data: Nine-month operating cash flow was $25.09 billion, against $18.59 billion a year earlier. Free cash flow in Q3, operating cash flow less capital expenditure of $859 million, was $4.26 billion, the sixth-lowest of the last 16 quarters. The company paid $6.17 billion in dividends and spent $5.03 billion on repurchases in nine months, together about 45% of operating cash flow (derived).

Why: The 10-Q attributes the nine-month gain to earnings, "timing of government payments," working capital and Inflation Reduction Act changes to pharmacy rebates, without splitting them. Timing items reverse, and the $5.9 billion drop from Q2 to Q3 is the size of what reversed or normalized. Repurchases of 13.8 million shares at an average $359.55, including 6.4 million at $312.73 under forward contracts settled July 1, cut the diluted count only 0.7% from a year earlier. The debt-to-capital ratio was 41.7% against 41.2% in Q2 and the roughly 40% the 8-K targets by year-end.

UnitedHealth Q3 2026 cash flow lines from the 10-Q

GeminIQ Financial Statements shows `Net Cash Provided By Used In Operating Activities` of $5.12 billion in Q3 2026 against $11.05 billion in Q2, with `Payments To Acquire Property Plant And Equipment` of $859 million. The highlight marks Q3 2026 operating cash flow.

A company whose cash conversion swings with government payment timing needs a full year, not one quarter, to show its true rate.

UnitedHealth's 2026 Guidance After Q3

UnitedHealth's October 13, 2026 8-K raised full-year 2026 diluted EPS guidance to at least $19.50 and adjusted EPS to at least $20.50, from $18.45 to $18.95 and $19.50 to $20.00 in July.

The Data: Nine-month diluted EPS was $17.50 (10-Q), so the July range implied a fourth quarter of $0.95 to $1.45. The new floor implies at least $2.00, against $4.56 in Q3 and $6.04 in Q2. The July outlook guided cash flows from operations of about $24.0 billion and repurchases of at least $5.0 billion; nine-month actuals are $25.09 billion and $5.03 billion.

Why: The floor sits above the old ceiling, so the raise is real, but "at least" removes the upper bound the July range carried. The implied $2.00 is less than half of Q3's EPS, and the filing does not say what drives the step down, only that the company's guidance incorporates experience through the third quarter. The company has guided a minimum, not a forecast, and a floor is met by any result above it.

How UNH Stock Has Moved After Past Earnings Reports

After UnitedHealth's last 12 10-Q filings with a completed one-month window (filed November 2023 to August 2026), the median one-month return was +3.7%, with 7 of 12 positive. The three-month median was also +0.8%, positive after 7 of 12.

The Data: One-month returns ranged from -22.8% (filed May 2025) to +25.0% (filed August 2025). Past Q3 filings were followed by +2.9% in 2023, +9.4% in 2024 and -13.0% in 2025. This filing's window has not elapsed. The GeminIQ Earnings Reaction Heat Map below covers 1-3 months after each 10-Q filing.

Why: The median hides a 48-point spread. These figures describe how UnitedHealth's stock moved after its past filings; they are a historical association, not a forecast.

UNH earnings reaction heat map, 1-3 months after each 10-Q filing

GeminIQ Earnings Reaction Heat Map shows UNH's cumulative return 1-3 months after each 10-Q filing. The highlight marks the one-month return after the FY2025 Q3 filing, -13.0%. The Q3 FY2026 cells are empty because the windows have not elapsed.

Institutions held 84.44% of UnitedHealth at June 30, 2026 (SEC Form 13F), up 4.72 points in a year and the highest of the quarters shown; the September 30 filings have not landed. Form 4 filings through August 21, 2026 show four sales totaling $955,000 and no purchases in the prior 12 months, against six purchases totaling $32.1 million in the 12 months before, the latest on May 16, 2025.

UNH institutional ownership by quarter

GeminIQ Institutional Ownership charts SEC Form 13F ownership by quarter end. The highlight marks June 30, 2026 at 84.44%.

A median near zero beside a range this wide means the history ranks the size of past moves, not their direction.

Frequently Asked Questions

How profitable is UnitedHealth?

UnitedHealth earned $15.87 billion attributable to shareholders in the nine months ended September 30, 2026, up 32%, a net margin of 4.7%. The 10-Q reports return on equity of 21.8% for the nine months. The debt-to-capital ratio was 41.7%.

Does UnitedHealth pay a dividend?

UnitedHealth paid a quarterly dividend of $2.32 per share on September 22, 2026, a total of $2.08 billion. The board raised the annual rate in June 2026 to $9.28 from $8.84, and nine-month cash dividends were $6.17 billion.

When does UnitedHealth report earnings?

UnitedHealth released Q3 2026 results on October 13, 2026 and filed the 10-Q on November 3. Q2 followed the same sequence, with the 8-K on July 16 and the 10-Q on August 10. Last year it filed its fourth-quarter results on March 2, 2026, a pattern, not a forecast of the next date.

Where can I verify UnitedHealth's Q3 2026 figures?

The figures come from the Q3 2026 10-Q and the October 13, 2026 earnings release, both on SEC EDGAR. Guidance and adjusted figures appear only in the release.

Start your 7-day free trial →

Wall Street's data. Main Street's price.

Institutional terminals charge thousands a year for as-filed accuracy. GeminIQ gives you the same thing for a fraction of the cost: financials built directly from raw SEC EDGAR filings, not third-party APIs, with full XBRL traceability back to the original 10-K or 10-Q. No normalized guesswork, just calculated metrics, charts, screeners, and watchlists built on numbers exactly as the company reported them. Start researching now at GeminIQ.com.

All financial figures cited in this article reference UnitedHealth Group Incorporated's Q3 2026 10-Q (filed November 3, 2026, period ending September 30, 2026), with guidance and management commentary drawn from the company's Form 8-K earnings release (filed October 13, 2026). All SEC filings are publicly available at SEC EDGAR and SEC EDGAR.

Disclaimer: The content in this blog is for educational and entertainment purposes only and does not constitute financial, legal, or tax advice. Investing involves risk, including the loss of principal. The views expressed are my own and not intended as financial advice or a guarantee of future performance.